VSIR and neoplasm: Genetic deletion or antibody-mediated blockade of VISTA synergizes with radiotherapy to enhance T cell responses and myeloid repolarization, improving tumor control across models and supporting VISTA as a promising combination partner for radiotherapy treatment regimen.